Cboe - Market News Story

Neovasc Receives Administrative Acceptance Review Notification For Premarket Approval Application From FDA For The Neovasc Reducer

Benzinga Newsdesk      1/15/2020 6:04:34 AM

Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of

Neovasc Inc. ("Neovasc" or the "Company") (NASDAQTSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt of an Administrative Acceptance Review Notification for the Company's Premarket Approval application ("PMA") from the U.S. Food and Drug Administration ("FDA") for its Neovasc Reducer™("Reducer") medical device for the treatment of refractory angina.